Abstract |
To evaluate the acute BP response to iv fenoldopam mesylate (FNP), 14 patients with severe hypertension (diastolic BP 120 to 170 mm Hg) were studied in an open-label trial. Initial infusion rate of FNP was 0.1 microgram/kg.min. Titration to diastolic BP goal (95 to 110 mm Hg) was followed by a constant infusion phase (greater than or equal to 6 h), a detitration phase (2 h), and a postinfusion phase. FNP reduced BP by 27/29 mm Hg (p less than .001) with no significant effect on heart rate. Maintenance of the BP effect was noted through the 6 h of constant rate infusion. Mild, transient vasodilating-associated adverse effects were noted with FNP. We conclude that FNP is an effective, well-tolerated iv antihypertensive agent for acute BP reduction in a severely hypertensive population.
|
Authors | M A Munger, W F Rutherford, L Anderson, A I Hakki, F M Gonzalez, E M Bednarczyk, G Emmanuel, S G Weed, E A Panacek, J A Green |
Journal | Critical care medicine
(Crit Care Med)
Vol. 18
Issue 5
Pg. 502-4
(May 1990)
ISSN: 0090-3493 [Print] United States |
PMID | 1970283
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Vasodilator Agents
- 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
- Fenoldopam
|
Topics |
- 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
(administration & dosage, analogs & derivatives, pharmacology, therapeutic use)
- Adult
- Aged
- Blood Pressure
(drug effects)
- Female
- Fenoldopam
- Heart Rate
(drug effects)
- Hemodynamics
(drug effects)
- Humans
- Hypertension
(drug therapy, etiology, physiopathology)
- Infusions, Intravenous
- Kidney
(drug effects)
- Male
- Middle Aged
- Vasodilator Agents
(therapeutic use)
|